Phenylketonuria (PKU) Treatment Market To Reach $2.69 Billion by 2035

Phenylketonuria (PKU) treatment market was valued at $1.24 billion in 2025 and is projected to reach $2.69 billion by 2035, growing at a CAGR of 8.1% during the forecast period (2026–2035). The increasing prevalence of rare genetic metabolic disorders and the growing adoption of newborn screening programs are major macro drivers supporting market growth. According to the World Health Organization (WHO), congenital disorders contribute to nearly 240,000 newborn deaths globally every year within 28 days of birth. Expanding early diagnosis initiatives and rising awareness regarding inherited metabolic disorders are increasing the demand for advanced PKU therapies, medical nutrition products, and enzyme replacement therapies worldwide.

Browse the full report description of “Phenylketonuria (PKU) Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Dietary Management, Drug Therapy, Gene Therapy, Enzyme Replacement/Substitution Therapy), By Dietary Management (Phenylalanine-Free Amino Acid Formulas, Glycomacropeptide (GMP)-Based Medical Foods, Low-Protein Foods, Nutritional Supplements), By End User (Hospitals, Specialty Metabolic Clinics, Homecare Settings, Research & Academic Institutes), Forecast Period (2026-2035)” at  https://www.omrglobal.com/industry-reports/phenylketonuria-treatment-market

The increasing implementation of newborn screening programs is significantly supporting market expansion. According to the U.S. Centers for Disease Control and Prevention (CDC), newborn screening enables early identification of conditions such as PKU before symptoms appear, helping reduce severe neurological complications through timely treatment interventions. In addition, the National Institutes of Health (NIH) estimates that PKU affects approximately 1 in every 10,000 to 15,000 newborns in the US. Growing healthcare expenditure, increasing investment in orphan drug development, and rising approval of innovative therapies are accelerating the treatment adoption rate globally. Hospitals and specialty metabolic clinics continue to dominate the end-user segment owing to the availability of specialized diagnostic and long-term disease management services.

Rising Adoption of Gene Therapy and Medical Nutrition Supporting Market Growth

The treatment type segment is witnessing strong growth due to increasing demand for dietary management and innovative drug therapies for lifelong PKU management. Dietary management remains the dominant segment due to the widespread adoption of low-phenylalanine medical foods and amino acid formulas as standard care practices. However, gene therapy and enzyme replacement/substitution therapy are expected to witness rapid growth owing to advancements in precision medicine and rare disease biotechnology pipelines. The increasing focus on improving patient compliance and quality of life is encouraging manufacturers to develop next-generation therapies and palatable nutritional formulations. Homecare settings are also emerging as a fast-growing end-user segment due to rising patient preference for long-term at-home nutritional management solutions.

Key Leaders Transforming the Phenylketonuria (PKU) Treatment Market

The key players in the phenylketonuria (PKU) treatment market include BioMarin Pharmaceutical Inc., Danone, Nestlé Health Science, PTC Therapeutics, Ajinomoto Co., Inc., among others. These companies are focusing on product innovation, orphan drug development, partnerships, and geographical expansion strategies to strengthen their market presence.

• In March 2026, Nestlé Health Science introduced Compleat Paediatric Oral Blends, an innovative oral nutritional supplement for children with special medical nutrition needs. The product, launched across several European markets, features fruit-based formulations with pea and rice proteins, vitamins, and minerals, supporting specialized dietary management solutions for pediatric metabolic disorders including PKU.
• In February 2026, BioMarin Pharmaceutical Inc. received approval from the U.S. Food and Drug Administration (FDA) for PALYNZIQ® (pegvaliase-pqpz) for adolescents aged 12 years and older with phenylketonuria (PKU). The approval expanded the use of the only enzyme substitution therapy approved for PKU and was supported by positive Phase 3 PEGASUS study results demonstrating significant reduction in blood phenylalanine levels compared to diet alone.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Treatment Type
• Dietary Management
• End User
• Competitive Landscape – BioMarin Pharmaceutical Inc., Danone, Nestlé Health Science, PTC Therapeutics, Ajinomoto Co., Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Phenylketonuria (PKU) Treatment Market Segmentation

By Treatment Type

• Dietary Management
• Drug Therapy
• Gene Therapy
• Enzyme Replacement/Substitution Therapy

By Dietary Management

• Phenylalanine-Free Amino Acid Formulas
• Glycomacropeptide (GMP)-Based Medical Foods
• Low-Protein Foods
• Nutritional Supplements

By End User

• Hospitals
• Specialty Metabolic Clinics
• Homecare Settings
• Research & Academic Institutes

Global Phenylketonuria (PKU) Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/phenylketonuria-treatment-market